Drugs 2005-01-01

Paricalcitol: a review of its use in the management of secondary hyperparathyroidism.

Dean M Robinson, Lesley J Scott

Index: Drugs 65(4) , 559-76, (2005)

Full Text: HTML

Abstract

Paricalcitol (Zemplar) is a synthetic vitamin D(2) analogue that inhibits the secretion of parathyroid hormone (PTH) through binding to the vitamin D receptor. It is approved in the US and in most European nations for intravenous use in the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure in adult, and in the US paediatric, patients. Paricalcitol effectively reduced elevated serum PTH levels and was generally well tolerated in children and adults with secondary hyperparathyroidism associated with chronic renal failure. In well designed clinical trials, paricalcitol was as effective as calcitriol and as well tolerated in terms of the incidence of prolonged hypercalcaemia and/or elevated calcium-phosphorus product (Ca x P). Thus, paricalcitol is a useful option for the management of secondary hyperparathyroidism in adults and children with chronic renal failure.

Related Compounds

  • Paricalcitol

Related Articles:

Paricalcitol, a vitamin d receptor activator, inhibits tumor formation in a murine model of uterine fibroids.

2014-09-01

[Reprod. Sci. 21(9) , 1108-19, (2014)]

Mesenchymal stem cells and a vitamin D receptor agonist additively suppress T helper 17 cells and the related inflammatory response in the kidney.

2014-12-15

[Am. J. Physiol. Renal Physiol. 307(12) , F1412-26, (2014)]

Spotlight on paricalcitol in secondary hyperparathyroidism.

2005-01-01

[Treat. Endocrinol. 4(3) , 185-6, (2005)]

Paricalcitol counteracts the increased contrast induced nephropathy caused by renin-angiotensin-aldosterone system blockade therapy in a rat model.

2014-10-01

[Eur. Rev. Med. Pharmacol. Sci. 18(19) , 2895-902, (2014)]

Vitamin D increases plasma renin activity independently of plasma Ca2+ via hypovolemia and β-adrenergic activity.

2013-10-15

[Am. J. Physiol. Renal Physiol. 305(8) , F1109-17, (2013)]

More Articles...